A Phase 3 interventional study of telmisartan+amlodipine and amlodipine in Hypertension, sponsored by Boehringer Ingelheim. Completed at 41 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-07-08.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.
Among the 99 studies testing telmisartan in Hypertension, this one is the 24th largest by enrollment, is one of 7 that started in 2007, is one of 40 in phase 3, and was the 31st registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:
Chong Kun Dang Pharmaceutical · Sites in Korea, Republic of
Ages 19–75
By country, each count listing its studies:
Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 5 · Phase 3 40 · Phase 4 32
First in 1997; this study’s year is marked. 7 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 531 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 184 across the 99 interventional studies. Of the 91 that completed or were terminated, 14 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
75 of 99 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
122 studies in Hypertension by Boehringer Ingelheim: 1 open now, 1 under way, 1 of them phase 3. Of 120 finished, 41 (34%) have results posted.
Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 29th largest by enrollment of the 74 interventional ones that give a count, is one of 7 that started in 2007, is one of 43 in phase 3, and was the 31st registered.
Boehringer Ingelheim’s Hypertension studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 99 studies testing telmisartan in Hypertension, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 122 in Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate that a fixed-dose combination of telmisartan 40 mg plus amlodipine 5 mg is superior to amlodipine 5 mg alone in patients with essential hypertension and inadequately controlled with amlodipine 5 mg monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pre-menopausal women who meet any one of the following 1 - 3:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: TelmisartanStudies of TelmisartanTelmisartan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AmlodipineStudies of AmlodipineAmlodipine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing)
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Time frame: Baseline and 8 Weeks
Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing)
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
Time frame: Baseline and 8 Weeks
Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline)
Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Time frame: 8 weeks
Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline)
Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
Time frame: 8 weeks
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline)
Adequate response defined that seated trough diastolic blood pressure was \<90 mmHg or decreased from reference baseline by \>=10 mmHg at 8 weeks
Time frame: 8 weeks
Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks
Adequate response defined that seated trough systolic blood pressure was \<140 mmHg or decreased from reference baseline by \>=20 mmHg at 8 weeks (0 percent at baseline)
Time frame: 8 weeks
Percentage of Patients With Optimal, Normal or High Normal Blood Pressure at 8 Weeks (0 Percent at Baseline)
Optimal, normal, high normal blood pressure were defined as follows: * Optimal: Systolic blood pressure (SBP) \< 120 mmHg and diastolic blood pressure (DBP) \< 80 mmHg * Normal: SBP \>= 120 mmHg or DBP \>= 80 mmHg and SBP \< 130 mmHg and DBP \< 85 mmHg * High normal: SBP \>= 130 mmHg or DBP \>= 85 mmHg and SBP \< 140 mmHg and DBP \< 90 mmHg * No: SBP \>= 140 mmHg and DPB \>= 90 mmHg
Time frame: 8 weeks
Clinically Relevant Abnormalities for Blood Chemistry, Pulse Rate, Laboratory Parameters and ECG
Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
Time frame: First administration of randomised treatment to 24 hours post last dose of randomised treatment
| Milestone | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Started | 269 | 262 |
| Completed | 264 | 257 |
| Not completed | 5 | 5 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: No visit within allowance period | 1 | 0 |
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Reduction From Reference Baseline in Mean Seated Diastolic Blood Pressure at Trough (24-hour Post-dosing) | 9.56 ± 0.61 | 4.45 ± 0.61 |
The mean of the change value was least square mean which was calculated by analysis of covariance with factor treatment and center, and covariate baseline.
| mmHg | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Reduction From Reference Baseline in Mean Seated Systolic Blood Pressure at Trough (24-hour Post-dosing) | 13.04 ± 0.88 | 5.77 ± 0.88 |
Seated trough diastolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
| percentage of patients | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Percentage of Patients With Seated Trough Diastolic Blood Pressure Less Than 90 mmHg at 8 Weeks (0 Percent at Baseline) | 68.1 | 47.1 |
Seated trough systolic blood pressure defined as blood pressure in a sitting position no later than 24 hours after the last intake
| percentage of patients | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Percentage of Patients With Seated Trough Systolic Blood Pressure Less Than 140 mmHg at 8 Weeks (0 Percent at Baseline) | 67.1 | 45.8 |
Adequate response defined that seated trough diastolic blood pressure was \<90 mmHg or decreased from reference baseline by \>=10 mmHg at 8 weeks
| percentage of patients | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Percentage of Patients Who Achieved an Adequate Response in Seated Trough Diastolic Blood Pressure at 8 Weeks (0 Percent at Baseline) | 74.5 | 50.2 |
Adequate response defined that seated trough systolic blood pressure was \<140 mmHg or decreased from reference baseline by \>=20 mmHg at 8 weeks (0 percent at baseline)
| percentage of patients | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Percentage of Patients Who Achieved an Adequate Response in Seated Trough Systolic Blood Pressure at 8 Weeks | 79.5 | 58.4 |
Optimal, normal, high normal blood pressure were defined as follows: * Optimal: Systolic blood pressure (SBP) \< 120 mmHg and diastolic blood pressure (DBP) \< 80 mmHg * Normal: SBP \>= 120 mmHg or DBP \>= 80 mmHg and SBP \< 130 mmHg and DBP \< 85 mmHg * High normal: SBP \>= 130 mmHg or DBP \>= 85 mmHg and SBP \< 140 mmHg and DBP \< 90 mmHg * No: SBP \>= 140 mmHg and DPB \>= 90 mmHg
| percentage of patients | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Optimal | 11.0 | 1.6 |
| Normal | 24.3 | 9.7 |
| High Normal | 26.6 | 23.0 |
Clinical relevant abnormalities for blood chemistry, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events.
| participants | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Alanine aminotransferase increased | 1 | 0 |
| Aspartate aminotransferase increased | 1 | 0 |
| Blood creatine phosphokinase increased | 2 | 0 |
| Blood potassium increased | 0 | 1 |
| Blood urine present | 1 | 0 |
| Liver function test abnormal | 1 | 0 |
| Bradycardia | 1 | 0 |
Collected over First administration of randomised treatment to 24 hours post last dose of randomised treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | — | 1/269 (0.4%) | 25/269 (9.3%) |
| Amlodipine 5 mg Monotherapy | — | 2/262 (0.8%) | 34/262 (13%) |
| Event | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| Angina pectorisCardiac disorders | 0/269 | 1/262 |
| Cerebellar infarctionNervous system disorders | 0/269 | 1/262 |
| Guillain-Barre syndromeNervous system disorders | 1/269 | 0/262 |
| Event | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy |
|---|---|---|
| NasopharyngitisInfections and infestations | 25/269 | 34/262 |
| Age, Continuous(years) | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy | Total |
|---|---|---|---|
| Mean | 57 ± 9.6 | 56 ± 9.9 | 56.5 ± 9.7 |
| Sex: Female, Male(Participants) | Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination | Amlodipine 5 mg Monotherapy | Total |
|---|---|---|---|
| Female | 72 | 76 | 148 |
| Male | 197 | 186 | 383 |
The record gives a start of Oct 2007 and a primary completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2010, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Telmisartan · Amlodipine